|
|
| FDA Approves Elan's MYOBLOC(TM) |
The First Type B Botulinum Toxin Therapy to Be Approved
DUBLIN, Ireland, Dec. 11 /PRNewswire/ -- Elan Corporation, plc
(NYSE: ELN) ("Elan") announced that the U.S. Food and Drug Administration
("FDA") approved MYOBLOC(TM) (Botulinum Toxin Type B) Injectable Solution.
New MYOBLOC Ready-to-Use Solution is a liquid formulation of botulinum
toxin that does not require reconstitution and is available in three
convenient vial configurations of 2,500 Units, 5,000 Units and 10,000 units,
providing maximum flexibility for dosing.
Donal J. Geaney, Chairman and Chief Executive Officer of Elan, commented,
"Our scientists have extensive experience in the development of biological
therapeutics, and we've applied this expertise to the development of MYOBLOC,
resulting in the only botulinum toxin therapy available as a ready-to-use
solution. We are excited to bring this new product to physicians and their
patients."
Elan Corporation, plc is a leading worldwide specialty pharmaceutical and
drug delivery company headquartered in Ireland, with its principal research,
development, manufacturing and marketing facilities located in Ireland, the
United States and Israel. Elan is focused on the discovery, development and
marketing of therapeutic products and services in neurology, pain management
and oncology, and on the development and commercialization of products using
its extensive range of proprietary drug delivery technologies. Elan shares
trade on the New York, London and Dublin Stock Exchanges.
The statements in this press release may include forward-looking
statements that involve risks and uncertainties including the difficulty of
predicting regulatory approvals, as well as other risks and uncertainties
detailed from time to time in periodic reports, including Elan's annual report
of Form 20-F for the fiscal year ended December 31, 1999, as amended by Elan's
Form 20-F/A1, both filed with the Securities and Exchange Commission. Actual
results may differ from the forward-looking statements.
SOURCE Elan Corporation plc
back to topRelated links:
Company News On-Call:
800-758-5804, ext. 231593
CONTACT:
Investors (U.S.) - Jack Howarth,
212-407-5740, 800-252-3526, Investors (Europe) - Emer Reynolds,
+353-1-709-4000, 00800-28352600, Media - Max Gershenoff,
212-407-5740, 800-252-3526, all for Elan Corporation, plc
